Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 and up

Effects of atorvastatin on inflammation in sleep apnea patients

Official title: Vascular Endothelial Dysfunction in Sleep Apnea

Run by Columbia University · NCT05289063 · Data updated 2026-11-12

This study is testing if taking atorvastatin daily can lower inflammation in people with obstructive sleep apnea who are using CPAP therapy.

More Obstructive Sleep Apnea of Adult trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment110 (estimated)
SponsorColumbia University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedOctober 3, 2022
Main results expectedFebruary 28, 2027
Study endsFebruary 28, 2027
Registry record updatedFebruary 13, 2026
Trial IDNCT05289063 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who have recently been diagnosed with obstructive sleep apnea and have not previously received CPAP treatment.

Probably not a fit

Patients with a history of coronary artery disease, heart failure, stroke, diabetes, malignancy, or other significant chronic conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to evaluate whether a daily dose of atorvastatin can reduce inflammatory markers in patients with obstructive sleep apnea (OSA) who are being treated with continuous positive airway pressure (CPAP). The study employs a double-blind, placebo-controlled design over a period of four weeks, focusing on two main objectives: the impact of statins on endothelial inflammation and pro-thrombotic conditions, and their effect on endothelial cholesterol metabolism in OSA patients. By investigating these factors, the study seeks to provide insights into potential cardiovascular risk reduction strategies for individuals with OSA.

Why it matters

Potential benefit: If successful, this study could lead to improved cardiovascular health for patients with obstructive sleep apnea.

How similar studies have gone: Previous studies have suggested that statins may have beneficial effects on cardiovascular risk factors, but this specific approach in OSA patients is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged ≥18 years
* Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.

Exclusion Criteria:

* A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years
* Regular use of any medications

Where it's running

  • Columbia University Irving Medical Center
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.